We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$733M
AUM Growth
+$21.5M
Cap. Flow
+$93.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
32.84%
Holding
138
New
34
Increased
32
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$25.7M
2
SKYE icon
Skye Bioscience
SKYE
+$15.4M
3
ASML icon
ASML
ASML
+$9.52M
4
CRM icon
Salesforce
CRM
+$8.99M
5
BBIO icon
BridgeBio Pharma
BBIO
+$8.86M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.9M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$9.57M
3
CAMT icon
Camtek
CAMT
+$6.97M
4
CATX icon
Perspective Therapeutics
CATX
+$6.61M
5
NVMI
Nova
NVMI
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 17.13%
3 Communication Services 3.05%
4 Consumer Discretionary 3%
5 Utilities 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$53.1M 7.24%
3,268,900
+136,200
+4% +$2.1M
SMH icon
2
PUT
VanEck Semiconductor ETF
SMH
$65.2B
$39.1M 5.33%
+149,800
New +$35.1M
BBIO icon
3
BridgeBio Pharma
BBIO
$15.7B
$23.1M 3.14%
910,070
+324,114
+55% +$8.86M
SNY icon
4
Sanofi
SNY
$103B
$21.8M 2.97%
449,515
-50,000
-10% -$2.41M
CYTK icon
5
Cytokinetics
CYTK
$10.5B
$20.9M 2.84%
384,924
+103,253
+37% +$6.23M
AMZN icon
6
Amazon
AMZN
$2.92T
$19.6M 2.67%
101,432
+47,000
+86% +$8.63M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.69B
$16.9M 2.3%
822,047
+9,083
+1% +$190K
META icon
8
Meta Platforms (Facebook)
META
$1.42T
$16.9M 2.3%
33,439
+8,000
+31% +$3.89M
AZN icon
9
AstraZeneca
AZN
$263B
$14.8M 2.02%
95,030
– –
MSFT icon
10
Microsoft
MSFT
$3.45T
$14.7M 2.01%
32,927
+5,379
+20% +$2.27M
NICE icon
11
Nice
NICE
$5.79B
$14M 1.91%
81,461
-4,420
-5% -$909K
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.57B
$13.2M 1.8%
83,659
+28,045
+50% +$3.6M
AAPL icon
13
Apple
AAPL
$4.54T
$13M 1.77%
61,500
+44,000
+251% +$8.21M
TEVA icon
14
Teva Pharmaceuticals
TEVA
$40.8B
$12.8M 1.75%
789,416
-1,100,284
-58% -$16.9M
KURA icon
15
Kura Oncology
KURA
$800M
$12.6M 1.72%
610,826
– –
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.45B
$12.1M 1.65%
293,832
+55,288
+23% +$2.36M
LLY icon
17
Eli Lilly
LLY
$1.02T
$11.9M 1.63%
13,190
-1,000
-7% -$800K
PRAX icon
18
Praxis Precision Medicines
PRAX
$8.58B
$11.7M 1.6%
283,424
+106,285
+60% +$5.02M
CLDX icon
19
Celldex Therapeutics
CLDX
$2.99B
$11.4M 1.56%
309,265
+32,269
+12% +$1.22M
NVO
20
Novo Nordisk
NVO
$208B
$11.1M 1.52%
78,080
-5,000
-6% -$663K
BIIB icon
21
Biogen
BIIB
$30B
$11M 1.5%
47,412
-23,234
-33% -$5.05M
QQQ icon
22
CALL
Invesco QQQ Trust
QQQ
$453B
$11M 1.5%
+22,900
New +$10.3M
SKYE icon
23
Skye Bioscience
SKYE
$20M
$10.4M 1.42%
+1,298,312
New +$15.4M
JSPR icon
24
Jasper Therapeutics
JSPR
$21M
$10.3M 1.41%
454,227
-51,015
-10% -$1.22M
JNJ icon
25
Johnson & Johnson
JNJ
$618B
$10.2M 1.39%
69,831
-10,000
-13% -$1.49M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sphera Funds Management held 138 positions worth $733M, up 3% from $712M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management deployed $93.1M of net new capital in Q2 2024, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Skye Bioscience: 1,298,312 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 65% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $16.9M trimmed.

  • Sphera Funds Management's largest Q2 2024 buy was Skye Bioscience: 1,298,312 shares worth $10.4M.
  • Sphera Funds Management added most to Broadcom in Q2 2024, an estimated $25.7M increase.
  • Sphera Funds Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $16.9M.
  • Sphera Funds Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $9.57M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $733M portfolio in Q2 2024.
  • Sphera Funds Management opened 34 new positions and closed 20 in Q2 2024.
  • Sphera Funds Management's portfolio value rose 3% quarter-over-quarter to $733M.

Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.